FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996242593> ?p ?o ?g. }

• W2996242593 abstract "Treatments that generate T cell-mediated immunity to a patient's unique neoantigens are the current holy grail of cancer immunotherapy. In particular, treatments that do not require cumbersome and individualized ex vivo processing or manufacturing processes are especially sought after. Here we report that AGI-134, a glycolipid-like small molecule, can be used for coating tumor cells with the xenoantigen Galα1-3Galβ1-4GlcNAc (α-Gal) in situ leading to opsonization with pre-existing natural anti-α-Gal antibodies (in short anti-Gal), which triggers immune cascades resulting in T cell mediated anti-tumor immunity.Various immunological effects of coating tumor cells with α-Gal via AGI-134 in vitro were measured by flow cytometry: (1) opsonization with anti-Gal and complement, (2) antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells, and (3) phagocytosis and antigen cross-presentation by antigen presenting cells (APCs). A viability kit was used to test AGI-134 mediated complement dependent cytotoxicity (CDC) in cancer cells. The anti-tumoral activity of AGI-134 alone or in combination with an anti-programmed death-1 (anti-PD-1) antibody was tested in melanoma models in anti-Gal expressing galactosyltransferase knockout (α1,3GT-/-) mice. CDC and phagocytosis data were analyzed by one-way ANOVA, ADCC results by paired t-test, distal tumor growth by Mantel-Cox test, C5a data by Mann-Whitney test, and single tumor regression by repeated measures analysis.In vitro, α-Gal labelling of tumor cells via AGI-134 incorporation into the cell membrane leads to anti-Gal binding and complement activation. Through the effects of complement and ADCC, tumor cells are lysed and tumor antigen uptake by APCs increased. Antigen associated with lysed cells is cross-presented by CD8α+ dendritic cells leading to activation of antigen-specific CD8+ T cells. In B16-F10 or JB/RH melanoma models in α1,3GT-/- mice, intratumoral AGI-134 administration leads to primary tumor regression and has a robust abscopal effect, i.e., it protects from the development of distal, uninjected lesions. Combinations of AGI-134 and anti-PD-1 antibody shows a synergistic benefit in protection from secondary tumor growth.We have identified AGI-134 as an immunotherapeutic drug candidate, which could be an excellent combination partner for anti-PD-1 therapy, by facilitating tumor antigen processing and increasing the repertoire of tumor-specific T cells prior to anti-PD-1 treatment." @default.
• W2996242593 created "2019-12-26" @default.
• W2996242593 creator A5008195566 @default.
• W2996242593 creator A5016869284 @default.
• W2996242593 creator A5019308362 @default.
• W2996242593 creator A5025524401 @default.
• W2996242593 creator A5032345203 @default.
• W2996242593 creator A5050487478 @default.
• W2996242593 creator A5065922220 @default.
• W2996242593 creator A5067373324 @default.
• W2996242593 creator A5069500944 @default.
• W2996242593 creator A5071061870 @default.
• W2996242593 creator A5072204509 @default.
• W2996242593 creator A5072325478 @default.
• W2996242593 creator A5080740048 @default.
• W2996242593 creator A5082956023 @default.
• W2996242593 creator A5084731018 @default.
• W2996242593 creator A5091002046 @default.
• W2996242593 date "2019-12-01" @default.
• W2996242593 modified "2023-10-11" @default.
• W2996242593 title "AGI-134: a fully synthetic α-Gal glycolipid that converts tumors into in situ autologous vaccines, induces anti-tumor immunity and is synergistic with an anti-PD-1 antibody in mouse melanoma models" @default.
• W2996242593 cites W1484684784 @default.
• W2996242593 cites W1525064473 @default.
• W2996242593 cites W1533481657 @default.
• W2996242593 cites W1584203472 @default.
• W2996242593 cites W1618744733 @default.
• W2996242593 cites W1751675114 @default.
• W2996242593 cites W1967660147 @default.
• W2996242593 cites W1984450355 @default.
• W2996242593 cites W1984743367 @default.
• W2996242593 cites W1986592145 @default.
• W2996242593 cites W1988329962 @default.
• W2996242593 cites W2005044790 @default.
• W2996242593 cites W200877045 @default.
• W2996242593 cites W2009048972 @default.
• W2996242593 cites W2011984976 @default.
• W2996242593 cites W2025163778 @default.
• W2996242593 cites W2028730899 @default.
• W2996242593 cites W2036963376 @default.
• W2996242593 cites W2039730154 @default.
• W2996242593 cites W2048769067 @default.
• W2996242593 cites W2059959414 @default.
• W2996242593 cites W2060070314 @default.
• W2996242593 cites W2064222196 @default.
• W2996242593 cites W2066812549 @default.
• W2996242593 cites W2068021104 @default.
• W2996242593 cites W2069592230 @default.
• W2996242593 cites W2079357428 @default.
• W2996242593 cites W2086951834 @default.
• W2996242593 cites W2088370636 @default.
• W2996242593 cites W2090842328 @default.
• W2996242593 cites W2093897123 @default.
• W2996242593 cites W2095592822 @default.
• W2996242593 cites W2097599440 @default.
• W2996242593 cites W2099540110 @default.
• W2996242593 cites W2110762398 @default.
• W2996242593 cites W2114783294 @default.
• W2996242593 cites W2116342473 @default.
• W2996242593 cites W2118486765 @default.
• W2996242593 cites W2123412929 @default.
• W2996242593 cites W2125354474 @default.
• W2996242593 cites W2127738393 @default.
• W2996242593 cites W2127836942 @default.
• W2996242593 cites W2128569116 @default.
• W2996242593 cites W2130867278 @default.
• W2996242593 cites W2136883776 @default.
• W2996242593 cites W2141982766 @default.
• W2996242593 cites W2143208041 @default.
• W2996242593 cites W2145898880 @default.
• W2996242593 cites W2148591507 @default.
• W2996242593 cites W2148631539 @default.
• W2996242593 cites W2161494348 @default.
• W2996242593 cites W2164009506 @default.
• W2996242593 cites W2168401979 @default.
• W2996242593 cites W2171720113 @default.
• W2996242593 cites W2186849568 @default.
• W2996242593 cites W2191574990 @default.
• W2996242593 cites W2291298003 @default.
• W2996242593 cites W2395113837 @default.
• W2996242593 cites W2539364080 @default.
• W2996242593 cites W2578530714 @default.
• W2996242593 cites W2588146309 @default.
• W2996242593 cites W2797578658 @default.
• W2996242593 doi "https://doi.org/10.1186/s12935-019-1059-8" @default.
• W2996242593 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6923872" @default.
• W2996242593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31889898" @default.
• W2996242593 hasPublicationYear "2019" @default.
• W2996242593 type Work @default.
• W2996242593 sameAs 2996242593 @default.
• W2996242593 citedByCount "9" @default.
• W2996242593 countsByYear W29962425932020 @default.
• W2996242593 countsByYear W29962425932021 @default.
• W2996242593 countsByYear W29962425932022 @default.
• W2996242593 countsByYear W29962425932023 @default.
• W2996242593 crossrefType "journal-article" @default.
• W2996242593 hasAuthorship W2996242593A5008195566 @default.
• W2996242593 hasAuthorship W2996242593A5016869284 @default.
• W2996242593 hasAuthorship W2996242593A5019308362 @default.
• W2996242593 hasAuthorship W2996242593A5025524401 @default.
• W2996242593 hasAuthorship W2996242593A5032345203 @default.

• next